Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease
| Autor: | Ingo Kilimann, Harald Hampel, Yuttachai Likitjaroen, Stefan J. Teipel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Aging
Pathology medicine.medical_specialty Neuroimaging Disease Normal aging methods [Diffusion Tensor Imaging] White matter pathology [Alzheimer Disease] Alzheimer Disease Neural Pathways Drug Discovery medicine drug therapy [Alzheimer Disease] Animals Humans ddc:610 Pharmacology Cognitive Intervention Surrogate endpoint business.industry drug effects [Neural Pathways] Brain Cognition drug effects [Aging] Diffusion Tensor Imaging medicine.anatomical_structure nervous system therapeutic use [Antipsychotic Agents] drug effects [Brain] business Neuroscience Diffusion MRI Antipsychotic Agents |
| Zdroj: | Current pharmaceutical design 19(36), 6416-6425 (2013). doi:10.2174/1381612811319360003 |
| DOI: | 10.2174/1381612811319360003 |
| Popis: | Introduction of diffusion tensor imaging (DTI) in 1980 and its advancement in the last three decades offered the possibility to visualize and quantify changes in white matter. DTI allows the evaluation of the structural integrity in complex neurodegenerative diseases, such as Alzheimer's disease (AD). Progressive disintegration of functional and structural neural network coordination contributes to the cognitive dysfunction in AD. Therefore, detection of loss of cortico-cortical projections may support an early diagnosis at prodromal stages of disease which may prove essential for future preventive AD treatment trials. Moreover, structural integrity measured by DTI may help to distinguish between symptomatic and disease modifying effects of pharmacological interventions. This review gives a concise account on the physical basis of DTI acquisition and processing. We summarize DTI findings in normal aging and AD and regarding the effects of cognitive intervention and antidementive treatment on structural neural connectivity. Finally, we evaluate the promising future potential of DTI to become a surrogate endpoint in clinical AD trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|